Evotec's Credibility Test: A Shrinking Base, a Widening Loss, and a Pipeline That Can't Get a Hearing
Published on 09/19/2026 at 08:41 | Editorial boerse-global.de
Evotec's management has a messaging problem, and the market is in no mood to help solve it. At Morgan Stanley's Global Healthcare Conference, CFO Claire Hinshelwood made the case that the Hamburg-based drug developer's core difficulty isn't scientific or operational at all — it's that investors fail to grasp how its research services, biologics unit, and partnership model fit together. The share price suggests the audience wasn't persuaded. Evotec closed Friday at EUR 2.90, down 47% since the start of the year, and touched a fresh 52-week low of EUR 2.77 during Tuesday's session.
The company's answer to this skepticism is "Horizon," an internal restructuring program meant to cut costs durably and restore profitability after a run of operational setbacks. Hinshelwood said the savings effort is tracking to plan and described the pipeline of pending deals as robust. The half-year figures for 2026 explain why the belt-tightening matters: revenue fell 19.2% year over year to EUR 300.1 million, while adjusted EBITDA swung to a loss of EUR 42.7 million from a shortfall of EUR 1.9 million a year earlier.
Full-year guidance, already slashed dramatically about three weeks ago, now points to revenue of EUR 570 million to EUR 610 million and an adjusted operating loss of EUR 70 million to EUR 105 million. The stock has shed a further 13.8% since that downgrade was confirmed.
A Bigger Share Count in a Falling Market
Compounding the operational doubts, Evotec disclosed a change in voting rights on Tuesday: following the issuance of subscription shares, total voting rights rose to 177,909,968. Whatever the balance-sheet logic behind the move, the timing lands badly. When a stock is already this weak, every additional share reads as extra weight — and the dilution has only deepened the skepticism around the name.
Should investors sell immediately? Or is it worth buying Evotec?
There has also been movement in the supervisory board, a further signal that does little to steady investor nerves.
Science Keeps Moving, the Tape Doesn't Care
The operational side, meanwhile, keeps producing headlines. Just-Evotec Biologics kicked off a Phase 1 clinical trial in early September for JST-018, an antibody cocktail targeting orthopoxviruses, advanced under the U.S. Department of War's Accelerated Antibodies Program. The candidate was developed end-to-end at the J.POD facility in Redmond — from sequence selection through process development to cGMP manufacturing.
Roughly two weeks ago, Evotec also announced a research collaboration with Plectonic Biotech to validate its in-house BiTco platform for solid tumors. The market's verdict was swift: the stock has lost 12.0% since that disclosure. Scientific alliances are bread and butter for a drug researcher, but with the base business contracting and operating losses widening, even innovative platforms struggle to build a floor under the shares. What investors want now is cost discipline and proof that the promised transformation is being executed — not distant milestones.
What Has to Happen Next
With a market capitalization of EUR 498.97 million, Evotec faces a straightforward but unforgiving task: convert its stated pipeline of deal closures into countable revenue, and soon. Until the company delivers hard evidence in coming quarters that the operating loss has stopped growing, the downside risks dominate. For anyone holding the stock, the position amounts to a patience test with little near-term relief — and catching this particular falling knife still looks like a gamble best left alone until the lowered guidance proves to be the bottom and the restructuring genuinely takes hold.
Ad
Evotec Stock: New Analysis - 19 September
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
